With approvals of novel cell and gene therapy products by the FDA anticipated to reach double figures in 2024 -- following eight US approvals in 2023 -- advancements in cell and gene therapy (CGT) products are paving the way for early-stage program developers. Now more than ever, it is critical to consider the end-product from the very beginning, establishing a scalable and robust process, and identifying opportunities to streamline without compromising on quality.
WIn this roundtable webinar, our expert panelists from across the CGT space will discuss a concept-to-cure program pathway, sharing insights and exploring challenges from a development, manufacturing, and testing perspective. Among the key audience takeaways will be: |
-
Key differences between material requirements for research vs. GMP vectors
- The importance of standardizing materials and manufacturing processes
- Real-world examples of how the pathway to the clinic can be streamlined
|
